Valvular heart disease-related mortality between middle- and high-income countries during 2000 to 2019
Background: Valvular heart disease (VHD) management has evolved rapidly in recent decades, but disparities in health care access persist among countries with varying socioeconomic backgrounds.
Objectives: The purpose of this study was to investigate global mortality trends from VHD and assess the difference between middle- and high-income countries.
Methods: We obtained mortality data from the World Health Organization Mortality Database for VHD and its subgroups (rheumatic valvular disease [RVD], infective endocarditis [IE], aortic stenosis [AS], and mitral regurgitation [MR]) from 2000 to 2019. Age-specific and age-standardized mortality rates per 100,000 persons in middle- and high-income countries were calculated, and trends were analyzed using joinpoint regression.
Results: A total of 93 countries (42 middle-income and 51 high-income) were included in the analysis. Both middle- and high-income countries showed an increasing trend in crude VHD mortality rate. In middle-income countries, the age-standardized VHD-related mortality rate was constant (0.0%/year), with decreasing RVD (-2.7%/year) and increasing IE, AS, and MR (0.8%/year, 2.0%/year, and 2.2%/year, respectively). In high-income countries, the age-standardized VHD-related mortality rate was decreasing (-0.6%/year). However, there was a rapid increase in mortality rate from IE in age ≤39 years after 2009 (7.0%/year). Moreover, there was a decreasing mortality rate from AS after 2015 but an increasing rate from MR after 2013, particularly in age ≥80 years.
Conclusions: Our study identified a rising burden of VHD-related mortality worldwide. The distribution and trends of VHD mortality differed between middle- and high-income countries. Further investigation is needed to understand the underlying etiology of these varying mortality trends in VHD and its subgroups.
Funding
St. Jude Medical, now Abbott
Boston Scientific (Chair, PEITHO trial)
Cleveland Clinic
Contego Medical (Chair, PERFORMANCE 2)
Duke Clinical Research Institute
Mayo Clinic, Mount Sinai School of Medicine
Daiichi Sankyo
Concept Medical
Alleviant Medical Novartis
Population Health Research Institute
Rutgers University
American College of Cardiology
Arnold and Porter
Baim Institute for Clinical Research
Boehringer Ingelheim
CSL Behring
Belvoir Publications
Canadian Medical and Surgical Knowledge Translation Research Group
Cowen and Company
Ferring Pharmaceuticals
Bayer
Abbott
Acesion Pharma
Afimmune
Aker Biomarine
Alnylam
Amarin
Amgen
AstraZeneca
Beren
Boston Scientific
Bristol-Myers Squibb
Cardax
CellProthera
Cereno Scientific
Chiesi
CinCor
Cleerly
Eisai
Ethicon
Faraday Pharmaceuticals
Forest Laboratories
Fractyl
Garmin
HLS Therapeutics
Idorsia
Ironwood
Ischemix
Janssen
Javelin
Lexicon
Lilly
Medtronic
Merck
Moderna
MyoKardia
NirvaMed
Novartis
Novo Nordisk
Otsuka
Owkin
Pfizer
PhaseBio
PLx Pharma
Recardio
Regeneron
Reid Hoffman Foundation
Roche
Sanofi
Stasys
Synaptic
The Medicines Company
Youngene
History
Comments
The original article is available at https://www.sciencedirect.com/Published Citation
Hibino M, et al. Valvular heart disease-related mortality between middle- and high-income countries during 2000 to 2019. 2024;101133.Publication Date
28 August 2024External DOI
PubMed ID
39817085Department/Unit
- Undergraduate Research
Publisher
ElsevierVersion
- Published Version (Version of Record)